Dr. Reddy's Laboratories Launches Nitroglycerin Sublingual Tablets USP in the U.S. Market Hyderabad, India, August 29, 2016
August 29 2016 - 5:23AM
Business Wire
Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE:
RDY) announced today that it has launched Nitroglycerin sublingual
tablets USP, 0.3 mg, 0.4 mg and 0.6 mg, a therapeutic equivalent
generic version of Nitrostat® (Nitroglycerin) sublingual tablets in
the US market on August 26, 2016, having been approved by the
United States Food & Drug Administration (USFDA).
The Nitrostat® (Nitroglycerin) sublingual tablet brand had U.S.
sales of approximately $ 108 Million MAT for the most recent twelve
months ending in March 2016 according to IMS Health*.
Dr. Reddy’s Nitroglycerin sublingual tablets USP, 0.4 mg is
available in bottle count size of 100 and a bundle of 4 bottles of
count size 25, Nitroglycerin sublingual tablets USP, 0.3mg is
available in bottle count size of 100 and the Nitroglycerin
sublingual tablets USP, 0.6mg is available in bottle count size of
100.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy’s operates in
markets across the globe. Our major markets include – USA, India,
Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com
Disclaimer: This press release may include statements of
future expectations and other forward-looking statements that are
based on the management’s current views and assumptions and involve
known or unknown risks and uncertainties that could cause actual
results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements
which are forward-looking by reason of context, the words "may",
"will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and
similar expressions identify forward-looking statements. Actual
results, performance or events may differ materially from those in
such statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults , currency exchange rates , interest rates , persistency
levels and frequency / severity of insured loss events (ii)
mortality and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization ,
including related integration issues.
The company assumes no obligation to update any information
contained herein.
Nitrostat® is a registered trademark of its respective
owner.
*IMS National Sales Perspective: Retail and Non-Retail MAT March
2016
RDY-0516-126
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160829005445/en/
Dr. Reddy's LaboratoriesINVESTOR RELATIONSSAUNAK SAVLA,
+91-40-49002135saunaks@drreddys.comorMEDIA RELATIONSCALVIN PRINTER,
+91-40- 49002121calvinprinter@drreddys.com